Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Контент предоставлен TGen Talks. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией TGen Talks или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Player FM - приложение для подкастов
Работайте офлайн с приложением Player FM !
Работайте офлайн с приложением Player FM !
Episode 63: Unlocking the Secrets of T Cell Therapy Resistance
MP3•Главная эпизода
Manage episode 375689946 series 1936276
Контент предоставлен TGen Talks. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией TGen Talks или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
For a patient diagnosed with multiple myeloma, a type of blood cancer, there are more treatment options than ever and traditional chemotherapies that cause debilitating side effects have been all but completely replaced by immunotherapies, treatments that help a patient's own immune system better fight the disease. But in many patients, a chosen immunotherapy drug can show great promise in early treatments, yet seemingly stop working altogether as time goes by. In a paper that was published in Nature Medicine, TGen's Dr. Jonathan Keats explains how upwards of 65% of relapsing multiple myeloma patients could be affected by mutations that impact targeted T cell treatments. On this episode, you'll hear about a study that found how these cancer cells were mutating to evade the very drugs prescribed to fight them. The findings could help clinicians and patients choose from among a variety of T cell therapies for multiple myeloma to find treatments that best match a patient’s available tumor targets. Dr. Keats also discusses his broader work in multiple myeloma and plans for a rapid sequencing center that will place valuable genomic-informed data in the hands of treating physicians in just 48 hours. All this and more on TGen Talks.
…
continue reading
77 эпизодов
MP3•Главная эпизода
Manage episode 375689946 series 1936276
Контент предоставлен TGen Talks. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией TGen Talks или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
For a patient diagnosed with multiple myeloma, a type of blood cancer, there are more treatment options than ever and traditional chemotherapies that cause debilitating side effects have been all but completely replaced by immunotherapies, treatments that help a patient's own immune system better fight the disease. But in many patients, a chosen immunotherapy drug can show great promise in early treatments, yet seemingly stop working altogether as time goes by. In a paper that was published in Nature Medicine, TGen's Dr. Jonathan Keats explains how upwards of 65% of relapsing multiple myeloma patients could be affected by mutations that impact targeted T cell treatments. On this episode, you'll hear about a study that found how these cancer cells were mutating to evade the very drugs prescribed to fight them. The findings could help clinicians and patients choose from among a variety of T cell therapies for multiple myeloma to find treatments that best match a patient’s available tumor targets. Dr. Keats also discusses his broader work in multiple myeloma and plans for a rapid sequencing center that will place valuable genomic-informed data in the hands of treating physicians in just 48 hours. All this and more on TGen Talks.
…
continue reading
77 эпизодов
Все серии
×Добро пожаловать в Player FM!
Player FM сканирует Интернет в поисках высококачественных подкастов, чтобы вы могли наслаждаться ими прямо сейчас. Это лучшее приложение для подкастов, которое работает на Android, iPhone и веб-странице. Зарегистрируйтесь, чтобы синхронизировать подписки на разных устройствах.